Press Releases April 16, 2026 08:00 PM

BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB896 Million in 2026

KANZHUN LIMITED reinforces shareholder value with substantial share repurchase program in 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, trading as BOSS Zhipin, announced continued share repurchases in 2026 totaling over RMB896 million, demonstrating its strong commitment to enhancing shareholder returns through its ongoing buyback program.

BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB896 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED repurchased 344,394 ordinary shares on April 16, 2026, for RMB17.1 million.
  • Year-to-date share repurchases exceed RMB896 million, reflecting a significant investment in the company's own stock.
  • The share repurchase program signals management's confidence in the company's future and dedication to increasing shareholder value.

BEIJING, April 17, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing nearly RMB17.1 million to repurchase 344,394 ordinary shares on April 16. Year-to-date in 2026, the Company has deployed over RMB896 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Share repurchases use substantial cash resources, which could otherwise be invested in growth opportunities, impacting future expansion.
  • Market conditions or regulatory changes could affect the continuation or effectiveness of the share repurchase program.
  • If the stock price does not respond positively, the buybacks might not translate into expected shareholder value enhancement.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026